Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

NCT06151574 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

428

Enrollment

INDUSTRY

Sponsor class

Conditions

Lung Cancer, Non-squamous, Non-small Cell

Interventions

DRUG: zongertinib
DRUG: pembrolizumab
DRUG: cisplatin
DRUG: carboplatin
DRUG: pemetrexed

Sponsor

Boehringer Ingelheim